The finding of these markers in the renal tissue of patients with NS and the association of BAFF expression with the worst renal prognosis also opens the door for the possible use of therapeutic strategies against BAFF (i.e., belimumab), which has demonstrated benefits in patients with SLE and lupus nephritis [16]. Here, TNFSF13B is linked to lupus nephritis.